Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Tg Therapeutics (TGTX) over the last 16 years, with Dec 2024 value amounting to -$1.0 million.

  • Tg Therapeutics' Cash from Investing Activities rose 596.71% to $46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year increase of 173.44%. This contributed to the annual value of -$1.0 million for FY2024, which is 97.95% up from last year.
  • Per Tg Therapeutics' latest filing, its Cash from Investing Activities stood at -$1.0 million for FY2024, which was up 97.95% from -$50.7 million recorded in FY2023.
  • Over the past 5 years, Tg Therapeutics' Cash from Investing Activities peaked at -$332,000 during FY2021, and registered a low of -$50.7 million during FY2023.
  • Over the past 3 years, Tg Therapeutics' median Cash from Investing Activities value was -$20.0 million (recorded in 2022), while the average stood at -$23.9 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first spiked by 98.65% in 2021, then crashed by 5,928.01% in 2022.
  • Yearly analysis of 5 years shows Tg Therapeutics' Cash from Investing Activities stood at -$24.5 million in 2020, then spiked by 98.65% to -$332,000 in 2021, then tumbled by 5,928.01% to -$20.0 million in 2022, then slumped by 153.09% to -$50.7 million in 2023, then soared by 97.95% to -$1.0 million in 2024.